Targeting Fibroblast-Derived Interleukin 6: A Strategy to Overcome Epithelial-Mesenchymal Transition and...

Area of Science:

• Oncology
• Cancer Biology
• Fibroblast-Cancer Cell Interactions

Background:

• Cancer-associated fibroblasts (CAFs) are key drivers of tumor progression, metastasis, and therapy resistance in head and neck squamous cell carcinoma (HNSCC).
• Understanding the mechanisms by which CAFs influence HNSCC aggressiveness is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the role of fibroblast-secreted IL-6 in driving epithelial-to-mesenchymal transition (EMT) and radioresistance in HNSCC.
• To evaluate the therapeutic potential of targeting the IL-6 signaling pathway in HNSCC.

Main Methods:

• Co-culture models of HPV-positive and HPV-negative HNSCC cells with fibroblasts.
• ELISA for IL-6 measurement, inhibitor studies (IL-6R, MAPK/ERK, JAK/STAT), EMT marker analysis, scratch and spheroid assays, and clonogenic assays for radioresistance evaluation.
• Establishment of radioresistant (RR) HNSCC cell lines to study EMT correlation.

Main Results:

• Fibroblasts induce EMT-like changes and radioresistance in HNSCC cells through IL-6 secretion.
• IL-6 receptor (IL-6R) and MAPK/ERK inhibitors reversed fibroblast-driven effects in both HPV-positive and negative HNSCC cells.
• Established RR cell lines displayed more aggressive phenotypes with pronounced EMT features, which were attenuated by targeting IL-6R or MAPK/ERK pathways.

Conclusions:

• Fibroblast-derived IL-6 critically drives EMT and radioresistance in HNSCC, leading to a more aggressive tumor phenotype.
• Targeting the IL-6/IL-6R/ERK pathway represents a promising therapeutic strategy for aggressive, therapy-resistant HNSCC.
• This pathway targeting may improve clinical outcomes for patients with advanced HNSCC.